178 related articles for article (PubMed ID: 33682017)
1. Prevalence and Factors Associated with Cumulative Anticholinergic Burden Among Older Long-Stay Nursing Home Residents with Overactive Bladder.
Chatterjee S; Walker D; Kimura T; Aparasu RR
Drugs Aging; 2021 Apr; 38(4):311-326. PubMed ID: 33682017
[TBL] [Abstract][Full Text] [Related]
2. Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries.
Aparasu RR; Sura S; Earla JR; Shiozawa A; Ng DB; Schermer CR
Adv Ther; 2020 Aug; 37(8):3584-3605. PubMed ID: 32638205
[TBL] [Abstract][Full Text] [Related]
3. The Costs and Healthcare Resource Utilization Associated with Anticholinergic Burden in Long-Stay Nursing Home Residents with Overactive Bladder in the US.
Chatterjee S; Walker D; Kimura T; Aparasu RR
Pharmacoecon Open; 2021 Dec; 5(4):727-736. PubMed ID: 34255290
[TBL] [Abstract][Full Text] [Related]
4. Anticholinergic Prescribing in Medicare Part D Beneficiaries Residing in Nursing Homes: Results from a Retrospective Cross-Sectional Analysis of Medicare Data.
Niznik J; Zhao X; Jiang T; Hanlon JT; Aspinall SL; Thorpe J; Thorpe C
Drugs Aging; 2017 Dec; 34(12):925-939. PubMed ID: 29214512
[TBL] [Abstract][Full Text] [Related]
5. A 12-Year Retrospective Study of the Prevalence of Anticholinergic Polypharmacy and Associated Outcomes Among Medicare Patients with Overactive Bladder in the USA.
Campbell NL; Hines L; Epstein AJ; Walker D; Lockefeer A; Shiozawa A
Drugs Aging; 2021 Dec; 38(12):1075-1085. PubMed ID: 34746992
[TBL] [Abstract][Full Text] [Related]
6. Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study.
Szabo SM; Gooch K; Schermer C; Walker D; Lozano-Ortega G; Rogula B; Deighton A; Vonesh E; Campbell N
BMJ Open; 2019 May; 9(5):e026391. PubMed ID: 31061036
[TBL] [Abstract][Full Text] [Related]
7. Cumulative Anticholinergic Burden and its Predictors among Older Adults with Alzheimer's Disease Initiating Cholinesterase Inhibitors.
Talwar A; Chatterjee S; Sherer J; Abughosh S; Johnson M; Aparasu RR
Drugs Aging; 2024 Apr; 41(4):339-355. PubMed ID: 38467994
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and predictors of anticholinergic medication use in elderly nursing home residents with dementia: analysis of data from the 2004 National Nursing Home Survey.
Chatterjee S; Mehta S; Sherer JT; Aparasu RR
Drugs Aging; 2010 Dec; 27(12):987-97. PubMed ID: 21087068
[TBL] [Abstract][Full Text] [Related]
9. Challenges in the Pharmacological Management of Nursing Home Residents with Overactive Bladder or Urinary Incontinence.
Zarowitz BJ; Allen C; O'Shea T; Tangalos EG; Berner T; Ouslander JG
J Am Geriatr Soc; 2015 Nov; 63(11):2298-307. PubMed ID: 26503458
[TBL] [Abstract][Full Text] [Related]
10. Anticholinergic burden and risk of cognitive impairment in elderly nursing home residents with depression.
Chatterjee S; Bali V; Carnahan RM; Chen H; Johnson ML; Aparasu RR
Res Social Adm Pharm; 2020 Mar; 16(3):329-335. PubMed ID: 31182419
[TBL] [Abstract][Full Text] [Related]
11. Higher Resource Utilization and Costs in Long-Term Nursing Home Residents With Overactive Bladder: A Retrospective Study of Medicare Beneficiaries.
Sura S; Shiozawa A; Ng D; Aparasu RR
J Am Med Dir Assoc; 2021 Jun; 22(6):1300-1306. PubMed ID: 33071158
[TBL] [Abstract][Full Text] [Related]
12. Anticholinergic Burden and Associated Healthcare Resource Utilization in Older Adults with Overactive Bladder.
Jaggi A; Nazir J; Fatoye F; Quelen C; Tu X; Ali M; Siddiqui E; Covernton PJO; Landeira M; Choudhury N
Drugs Aging; 2021 Oct; 38(10):911-920. PubMed ID: 34386936
[TBL] [Abstract][Full Text] [Related]
13. Risk of Mortality Associated with Anticholinergic Use in Elderly Nursing Home Residents with Depression.
Chatterjee S; Bali V; Carnahan RM; Chen H; Johnson ML; Aparasu RR
Drugs Aging; 2017 Sep; 34(9):691-700. PubMed ID: 28656508
[TBL] [Abstract][Full Text] [Related]
14. The Relationship Between Anticholinergic Exposure and Falls, Fractures, and Mortality in Patients with Overactive Bladder.
Suehs BT; Caplan EO; Hayden J; Ng DB; Gaddy RR
Drugs Aging; 2019 Oct; 36(10):957-967. PubMed ID: 31359329
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States.
Chen JV; Klein TM; Nesheim J; Mudd PN
J Med Econ; 2022; 25(1):1092-1100. PubMed ID: 35993729
[TBL] [Abstract][Full Text] [Related]
16. Treatments for overactive bladder: focus on pharmacotherapy.
Geoffrion R;
J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
[TBL] [Abstract][Full Text] [Related]
17. Decrease of Anticholinergic Drug Use in Nursing Home Residents in the United States, 2009 to 2017.
Malagaris I; Mehta HB; Li S; Goodwin JS
J Am Geriatr Soc; 2020 Dec; 68(12):2797-2804. PubMed ID: 32798337
[TBL] [Abstract][Full Text] [Related]
18. Overactive bladder in an integrated delivery system: a longitudinal cohort study.
Linder JA; Weissman JS; Reyes Nieva H; Lipsitz S; Haring RS; DeAngelis J; Kristy RM; Loughlin KR
BMC Health Serv Res; 2020 May; 20(1):447. PubMed ID: 32434511
[TBL] [Abstract][Full Text] [Related]
19. Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA.
Chen JV; Gahn JC; Nesheim J; Mudd PN
Pharmacoeconomics; 2022 Oct; 40(10):979-988. PubMed ID: 35881325
[TBL] [Abstract][Full Text] [Related]
20. Anticholinergic Medication Use and Risk of Fracture in Elderly Adults with Depression.
Chatterjee S; Bali V; Carnahan RM; Chen H; Johnson ML; Aparasu RR
J Am Geriatr Soc; 2016 Jul; 64(7):1492-7. PubMed ID: 27294403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
